688176 亚虹医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-16.286-23.486-17.628-15.524-8.525
总资产报酬率 ROA (%)-12.222-19.455-15.821-14.545-8.256
投入资产回报率 ROIC (%)-13.052-20.695-16.609-15.076-8.472

边际利润分析
销售毛利率 (%)74.24774.03375.54078.99873.022
营业利润率 (%)-156.208-154.563-190.415-2,937.490-948,649.406
息税前利润/营业总收入 (%)-154.692-154.807-199.958-3,197.334-1,037,721.275
净利润/营业总收入 (%)-157.668-156.157-191.504-2,914.455-944,804.606

收益指标分析
经营活动净收益/利润总额(%)104.487103.654105.337107.943125.221
价值变动净收益/利润总额(%)-5.309-5.040-6.322-6.324-23.476
营业外收支净额/利润总额(%)0.8571.1720.773-0.623-0.932

偿债能力分析
流动比率 (X)6.4534.3787.76912.81634.217
速动比率 (X)6.3514.3247.73912.80834.182
资产负债率 (%)27.77624.03111.3649.2133.583
带息债务/全部投入资本 (%)18.27815.7033.6763.065-0.130
股东权益/带息债务 (%)427.041522.3762,548.5543,089.060-76,383.985
股东权益/负债合计 (%)263.916318.815779.598984.7232,690.805
利息保障倍数 (X)-53.983-97.44524.81211.50010.607

营运能力分析
应收账款周转天数 (天)139.535102.92761.240113.751141.021
存货周转天数 (天)105.57369.42727.202274.394168,675.349